Abstract | INTRODUCTION: MATERIAL AND METHODS: In two hemodialysis units, 58 patients were randomly assigned into two groups, to receive two different anticoagulation protocols for 3 weeks; one group continued to receive their routine dose of UF heparin, 5000 units, and the other received enoxaparin, 0.5 mg/kg, at the beginning of each hemodialysis session. RESULTS: While there was no significant difference between baseline blood measurements of the two groups in terms of kidney function tests and electrolytes, following 3 weeks of the study, the mean serum potassium level decreased from 4.9 ± 0.8 mEq/L to 4.5 ± 0.5 mEq/L in the LMW heparin group (P = .001); however, there was no change in the mean serum potassium level in those who continued to receive their usual dose of UF heparin. In a subgroup analysis, diabetic patients in the enoxaparin group did not experience significant reduction in serum potassium levels. CONCLUSIONS: Our study revealed the role of LMW heparins as a potential alternative to UF heparins in the hemodialysis patients with hyperkalemia.
|
Authors | Shahrokh Ezzatzadegan Jahromi, Mohammad Saleh Mahmoodi, Fatemeh Behroozi, Jamshid Roozbeh, Fatemeh Emamghoreishi |
Journal | Iranian journal of kidney diseases
(Iran J Kidney Dis)
Vol. 8
Issue 6
Pg. 475-80
(Nov 2014)
ISSN: 1735-8604 [Electronic] Iran |
PMID | 25362223
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticoagulants
- Heparin, Low-Molecular-Weight
- Heparin
- Potassium
|
Topics |
- Anticoagulants
(administration & dosage, therapeutic use)
- Female
- Heparin
(administration & dosage, therapeutic use)
- Heparin, Low-Molecular-Weight
(administration & dosage, therapeutic use)
- Humans
- Hyperkalemia
(drug therapy)
- Male
- Middle Aged
- Potassium
(blood)
- Random Allocation
- Renal Dialysis
|